Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics and investor sentiment in the market [1]. Shareholder Reductions - Guosheng Securities: Three shareholders plan to collectively reduce their holdings by no more than 2.82% [1] - Binjiang Group: Multiple shareholders intend to reduce their stakes by up to 2.88% [1] - Kanglong Chemical: Shareholder Xincheng Kang and its concerted parties plan to reduce their holdings by no more than 1.5% [1] - Erliang San: Controlling shareholder Li Xiaolong intends to reduce his stake by no more than 1% [1] - Yongxing Shares: Science City Investment Group plans to reduce its holdings by no more than 1% [1] - Weike Technology: Industrial Investment intends to reduce its stake by no more than 0.9999% [1] - Zhengyuan Wisdom: Plans to reduce no more than 2% of repurchased shares [1] - Baida Group: Shareholder Xizi United plans to reduce up to 752.48 million shares [1] - Camel Shares: Chairman Liu Changle intends to reduce no more than 7.2 million shares [1] - Zhongwei Company: Xunxin Investment has cumulatively reduced 12.52 million shares through block trading [1] - Aerospace Engineering: Guochuang Fund and New Car Fund have collectively reduced 2.76 million shares [1] - Tengya Precision: Nanjing Yunhang has cumulatively reduced 2.49% of its shares [1] - Hexing Packaging: Xia Ping and its concerted parties have cumulatively reduced 3.4045% of their shares [1] Other Notable Information - *ST Dazheng: Shareholder Zhou Zhenke's 0.81% stake is set to be forcibly sold by judicial order [1] - Dongbai Group: Lacks duty-free operating qualifications and is not involved in duty-free goods operations [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has received a share reduction plan notification from its major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder 信中康成 holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce its holdings by up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shareholder 信中龙成 holds 28,498,500 shares, about 1.60% of the total share capital, and intends to reduce its holdings by up to 17,781,955 shares, representing 1% of the total share capital, within the same three-month period [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has announced that its major shareholders, 深圳市信中康成投资合伙企业 and 深圳市信中龙成投资合伙企业, plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - 深圳市信中康成 plans to reduce its holdings by up to 8.891 million shares, which represents 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成 plans to reduce its holdings by up to 17.782 million shares, which represents 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (300759.SZ) announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) plans to reduce its holdings by up to 8.891 million shares, representing 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglongcheng Investment Partnership (Limited Partnership) intends to reduce its holdings by up to 17.782 million shares, accounting for 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (SZ 300759) announced a share reduction plan from major shareholders, which may impact the stock's performance and investor sentiment [1] Shareholder Reduction Plan - Shenzhen Xinchongkang Investment Partnership plans to reduce its holdings by up to approximately 8.89 million shares, accounting for 0.5% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglong Investment Partnership plans to reduce its holdings by up to approximately 17.78 million shares, accounting for 1% of the total share capital, within the same timeframe [1] Financial Performance - For the year 2024, Kanglong Chemical's revenue composition is as follows: 99.95% from scientific research and technical services, and 0.05% from other businesses [1] - As of the report date, Kanglong Chemical's market capitalization stands at 56 billion yuan [1]

Core Viewpoint - The company announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xindlongcheng Investment Partnership (Limited Partnership) holds 28,498,500 shares, approximately 1.60% of the total share capital, and plans to reduce up to 17,781,955 shares, which is 1% of the total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - 康龙化成 announced a share reduction plan by major shareholders, which may impact the stock's market performance and investor sentiment [1] Shareholder Reduction Plans - 深圳市信中康成投资合伙企业 plans to reduce its holdings by up to 8,890,977 shares, representing approximately 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成投资合伙企业 intends to reduce its holdings by up to 17,781,955 shares, accounting for about 1% of the total share capital, also within three months starting from December 8, 2025 [1] - 信中康成 currently holds 223,488,310 shares, which is about 12.57% of the total share capital, while 信中龙成 holds 28,498,500 shares, approximately 1.60% of the total share capital [1]

Pharmaron Beijing Co., Ltd. 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年11月14日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-064 康龙化成（北京）新药技术股份有限公司 ...

人民财讯11月14日电，康龙化成（300759）11月14日公告，合计持股14.17%的公司股东深圳市信中康 成投资合伙企业(有限合伙)(简称"信中康成"))及其一致行动人深圳市信中龙成投资合伙企业(有限合伙) 计划合计减持公司股份不超过2667.29万股，占公司总股本的1.5%。 ...

康龙化成(300759.SZ)公告称，持股5%以上股东信中康成计划减持不超过889.10万股（占公司总股本的 0.50%），一致行动人信中龙成计划减持不超过1,778.20万股（占公司总股本的1.00%），合计减持不超 过2,667.30万股（占公司总股本的1.50%）。减持方式为集中竞价交易或大宗交易，减持原因为合伙企 业存续期限即将到期及自身资金需求，减持期间为公告披露之日起15个交易日后的3个月内。 ...